1. The number of patients with NON SMALL CELL LUNG CARCINOMA (Stage IIIB/Stage IV) treated in the last 6 months with the following:
Afatinib (Giotrif)
Ceritinib (Zykadia)
Crizotinib (Xalkori)
Erlotinib (Tarceva)
Gefitinib (Iressa)
Pemetrexed (Alimta)
Nivolumab (Opdivo)
Nintedanib (Vargatef)

2. The number of patients with METASTATIC MELANOMA Stage IV (advanced or metastatic), treated in the last 6 months with the following:
Ipilimumab (Yervoy)
Nivolumab (Opdivo)
Ipilimumab AND Nivolumab
Pembrolizumab (Keytruda)
Vemurafenib (Zelboraf)
Vemurafenib AND Cobimetinib
Dabrafenib (Taflinar)
Trametinib (Mekinist)
Dabrafenib AND trametinib
Dacarbazine (DTIC)
For the period 1/1/2016-30/06/2016

Download response Carcinoma and melanoma 230916